Fundraising Fox
🦊/People
Sign in

Vincent Miles

Investor

Partner at Abingworth · Director at IFM Tre

Boston, Massachusetts

Writes $15M – $30M checks · typically $22.5M

Find your path to Vincent

267 people in our graph share verified history with Vincent — schools, employers, funds. One of them is your warm intro.

Michael TaylorunlockedVincent: together at Pharmacia Biotech (1986–1992)
×4Vincent: together at Dana Farber Cancer Institute
Vincent: together at Alnylam
×6Vincent: together at Pharmacia Biotech

About

Vincent Miles is an Executive Director at Abingworth, which he joined in 2007, where he helps identify and evaluate new business opportunities and supports portfolio companies. He previously served as Senior Vice President of Business Development at Alnylam Pharmaceuticals and held VP roles at Millennium Pharmaceuticals, and earlier led the technology transfer office at the Dana-Farber Cancer Institute and held positions at RiboGene, Pharmacia, and Amersham International. He holds a BSc in Biochemistry and a PhD in Biochemical Embryology from University College London.

Contact· self-published, not guessed

Invests in

Biotech

Director at IFM Tre

Intro paths

→

In turn, Vincent can intro founders to IFM Tre's investors below.

IFM Tre's investors · 2

AbingworthLondon · $15M – $30M checks · since 2018Atlas VentureCambridge · $500K – $1M checks · since 2018

Co-founders at IFM Tre

GD
Gary D GlickExecutive Officer, Director

Experience

  1. AbingworthExecutive Directorcurrent2022 — presentGreater Boston
  2. AbingworthPartner2007 — 2022Boston, Massachusetts, United States
  3. Alnylam PharmaceuticalsSenior VP, Business Development2003 — 2007
  4. Millennium PharmaceuticalsVP, Business Development, Technology Management1997 — 2003
  5. Dana Farber Cancer InstituteDirector, Office of Technology Transfer1996 — 1997
  6. RiboGene (a predecessor of Questcor)VP, R&D and Business Development1992 — 1996
  7. Pharmacia BiotechVP, International Marketing (Molecular Biology Division)1989 — 1992
  8. Pharmacia BiotechVP, R&D (Molecular Biology Division)1986 — 1990
  9. Amersham InternationalR&D and Business Development1978 — 1986
  10. Home Office Forensic Science LaboratoryHigher Scientific Officer1975 — 1978

Skills & more

Strategic Planning3Strategy4Management1R&D23Business Development22Commercialization8Technology Transfer27Start-ups7Biology2Licensing5Corporate Development8Competitive Analysis3
+12 moreVenture CapitalMergersLifesciencesBiotechnologyDue DiligenceEntrepreneurshipPharmaceutical IndustryOncologyBusiness PlanningBusiness StrategyMergers & AcquisitionsDrug Development

From Vincent's professional profile.

Investments

Board seats

Atsena TherapeuticsBrave BioChiasmaDicerna PharmaceuticalsDynex TechnologiesHydra BiosciencesIFM DueIFM TherapeuticsIFM TreMagellan DiagnosticsNido BiosciencesPersonalisPrimeraDx

Investor

ChiasmaHydra BiosciencesPrimeraDx (Primera Biosystems)

Sources: the firm's website · curated public sources.

Colleagues at Abingworth

Alex Asquith
Counsel at Abingworth
Amit Khasgiwala
Investment Professional at Innovatus Capital Partners
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Ysios Capital
David Leathers
General Partner at Abingworth

Frequently asked questions

Who is Vincent Miles?
Vincent Miles is an Executive Director at Abingworth, which he joined in 2007, where he helps identify and evaluate new business opportunities and supports portfolio companies. He previously served as Senior Vice President of Business Development at Alnylam Pharmaceuticals and held VP roles at Millennium Pharmaceuticals, and earlier led the technology transfer office at the Dana-Farber Cancer Institute and held positions at RiboGene, Pharmacia, and Amersham International. He holds a BSc in Biochemistry and a PhD in Biochemical Embryology from University College London.
Where does Vincent Miles work?
Vincent Miles is Partner at Abingworth.
What does Vincent Miles invest in?
Vincent Miles invests in Biotech.
What check size does Vincent Miles write?
Vincent Miles typically writes checks of $15M – $30M.
What boards does Vincent Miles sit on?
Vincent Miles holds tracked board seats at Atsena Therapeutics, Brave Bio, Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Hydra Biosciences, IFM Due, IFM Therapeutics, IFM Tre, Magellan Diagnostics.
What companies has Vincent Miles invested in?
Investments tracked here include Chiasma, Hydra Biosciences, PrimeraDx (Primera Biosystems).
Where did Vincent Miles go to school?
Vincent Miles studied at UCL (B.Sc. (biochemistry), Ph.D. (biochemical embryology/molecular biology)).

Same school

Shared employers